

# Disorders Caused by Toxins

Botulinum neurotoxin · Curare · Neuromuscular transmission

**Presynaptic toxin**

**Postsynaptic toxin**

**Dr Abu Suraih Sakhri**

MBBS, MD (Pathology)


[www.abusuraihsakhri.com](http://www.abusuraihsakhri.com)

# Learning objectives

- Localize neuromuscular dysfunction to the presynaptic terminal or postsynaptic endplate.
- Explain how botulinum toxin interrupts acetylcholine release and produces flaccid paralysis.
- Contrast botulinum toxin with curare and selected immune-mediated junction disorders.
- Recognize urgent clinical consequences and the principles of confirmation and support.

# Why toxins belong in neuromuscular pathology


- Transmission may fail even when nerve and muscle fibers remain anatomically present.
- Biologic and plant-derived toxins reveal distinct vulnerable sites in the junction.
- Clinical expression is predominantly painless weakness rather than sensory loss.



Presynaptic output <sup>Schematic</sup> Postsynaptic reception


# Anatomy of the motor endplate

- Motor axons terminate as presynaptic boutons on individual skeletal myofibers.
- A synaptic cleft separates the axon terminal from the specialized sarcolemma.
- Postsynaptic membrane folds concentrate acetylcholine receptors.



# The normal transmission sequence


- A motor action potential reaches the nerve terminal.
- Acetylcholine-containing vesicles release transmitter into the cleft.
- Receptor activation generates a signal that initiates skeletal muscle contraction.



Schematic

# Presynaptic boutons are secretory structures


- Terminal swellings are positioned to release acetylcholine near the endplate.
- The synaptic vesicle must fuse with the terminal membrane to release its contents.
- Botulinum neurotoxin disables this exocytotic step.



Schematic

# Acetylcholine must reach the receptor


- Acetylcholine exits the motor terminal rather than crossing the cleft in vesicles.
- The synaptic cleft is the extracellular space between bouton and sarcolemma.
- Blockage before release deprives intact receptors of their ligand.



Schematic

# Postsynaptic membrane specialization

- ACh receptors cluster on folded regions of the muscle sarcolemma.
- Spatial receptor organization supports efficient conversion of a chemical signal to contraction.
- Curare acts at this receptor level rather than on synaptic vesicle fusion.



Schematic

# The critical two-site distinction

- Presynaptic failure: Insufficient transmitter becomes available in the cleft.
- Postsynaptic failure: Available transmitter cannot produce a normal receptor response.
- Both routes reduce neuromuscular activation and cause weakness.

## Presynaptic lesion

Failure of  
acetylcholine  
delivery

Botulinum toxin


## Postsynaptic lesion

Failure of  
acetylcholine  
reception

Curare

# Why weakness can be painless

- The immediate defect concerns neuromuscular activation, not destruction of pain fibers.
- Robbins groups neuromuscular junction disorders by painless weakness and fatigue.
- A normal-appearing muscle does not exclude major transmission failure.



Schematic

# Three different causes of junction failure

- Toxins directly interfere with transmitter release or receptor occupancy.
- Autoantibodies impair presynaptic calcium-channel function or postsynaptic proteins.
- Inherited defects alter junction proteins and produce congenital myasthenic syndromes.

## Acquired toxic

Botulinum toxin

Curare


## Other causes

Immune-mediated  
disease

Inherited protein  
defects

# Localization before disease naming

- Ask whether the exposure affects the motor nerve terminal or endplate receptor.
- Determine whether the resulting dysfunction reduces release or receptor effectiveness.
- Use pattern of weakness, exposure history, and supportive testing to distinguish etiologies.



Schematic

## Two principal agents in this lecture

- Botulinum neurotoxin: A bacterial protein that inhibits acetylcholine release.
- Curare: Plant-derived substances that antagonize acetylcholine receptors.
- Both impair transmission and may produce flaccid paralysis by different mechanisms.

### **Botulinum neurotoxin**

Bacterial exotoxin

Presynaptic effect


### **Curare**

Plant-derived  
compounds

Postsynaptic effect

# Botulinum neurotoxin as a bacterial exotoxin

- Botulinum toxin as a bacterial protein with a binding and an enzymatic component.
- Its catalytic activity modifies proteins involved in neurotransmitter secretion.
- The effect is functional synaptic blockade rather than obligatory neuronal death.



Schematic

# Microbiologic origin of botulism

- The organism is an anaerobic, gram-positive, spore-forming bacillus.
- Related toxin-producing clostridia can rarely cause similar clinical botulism.
- The disease is attributable to biologically active botulinum neurotoxin.

**C. Botulinum**

Toxin-mediated neuromuscular paralysis

# Protein domains explain toxin specificity

- A binding component directs the protein to susceptible nerve endings.
- An enzymatic light-chain component modifies the transmitter-release apparatus.
- Selectivity for synaptic machinery explains the characteristic physiologic deficit.

## **Binding / entry**


Access to presynaptic terminal

## **Enzymatic injury**

Cleavage of vesicle-fusion proteins

# Botulism is not a single exposure pathway


- Preformed toxin can be consumed in contaminated food.
- Clostridial growth in wounds can generate toxin within the host.
- Intestinal colonization and excessive therapeutic or cosmetic exposure are additional routes.



Schematic

# Foodborne botulism: Preformed toxin


- The relevant exposure is ingestion of toxin already present in food.
- A food-linked history may connect multiple symptomatic individuals.
- Systemic effects ultimately reflect inhibition of neuromuscular transmission.



Schematic

# Wound botulism: Local production, systemic effect

- Organisms in an infected wound can produce botulinum neurotoxin.
- Toxin reaches distant nerve terminals and acts outside the wound.
- The extent of paralysis does not require destructive infection of skeletal muscles.



Schematic

# Intestinal colonization botulism

- In infant botulism, ingested spores can colonize the immature intestine.
- Toxin production in the gut precedes neuromuscular effects.
- The intestinal pathway differs mechanistically from consuming preformed toxin.

## Foodborne intoxication

Toxin already in food

Ingestion of active toxin

## Infant colonization

Spores colonize intestine

Toxin generated in vivo

# Iatrogenic botulism: Systemic toxicity after use

- Botulinum toxin is also used intentionally for local muscular effects.
- Systemic spread after injection can produce a syndrome resembling natural botulism.
- The mechanism remains presynaptic interruption of acetylcholine release.

## **Therapeutic intent**


Localized selected-muscle effect

## **Unwanted toxicity**

Excessive or distant neuromuscular weakness

# Motor nerve terminals are the principal target


- Botulinum neurotoxin reaches cholinergic presynaptic endings.
- The target is the apparatus that releases acetylcholine into the motor endplate cleft.
- The postsynaptic acetylcholine receptor is not directly blocked by botulinum toxin.



Schematic

# Initial binding to presynaptic membranes


- Toxin binding to gangliosides on motor neurons.
- Neuronal surface recognition initiates toxin entry into the cell.
- Binding specificity helps explain why neural secretion is the key affected function.



Schematic

# Internalization precedes intracellular cleavage

- Surface attachment alone does not explain sustained functional inhibition.
- Following entry, the toxin's catalytic component reaches the neuronal cytoplasm.
- The functional target is the protein machinery governing synaptic vesicle fusion.



Schematic

# SNARE proteins couple vesicles to the membrane

- Synaptobrevin (VAMP), SNAP-25, and syntaxin participate in exocytotic fusion.
- The assembled fusion apparatus allows vesicles to discharge transmitter.
- Cleaving a required component stops efficient acetylcholine release.

## **Intact SNARE system**

Vesicle fusion proceeds

## **Cleaved SNARE system**

ACh exocytosis fails


## The serotype matters for the exact substrate

- Synaptobrevin is one of several SNARE protein substrates.
- Different botulinum neurotoxin serotypes target different SNARE proteins.
- The shared endpoint is blockade of transmitter-containing vesicle fusion.

| Illustrative toxin serotype | Established protein target |
|-----------------------------|----------------------------|
| A / E                       | SNAP-25                    |
| B / D / F / G               | Synaptobrevin (VAMP)       |
| C                           | Syntaxin and SNAP-25       |

# Blocked fusion means blocked transmitter release


- A vesicle may remain intact but cannot efficiently merge with the nerve terminal membrane.
- Consequently less acetylcholine enters the synaptic cleft.
- Muscle receptor activation falls despite the receptor itself remaining the indirect target.



Schematic

# From the molecule to the patient's weakness

- SNARE protein cleavage reduces acetylcholine output.
- Insufficient endplate activation prevents reliable muscle contraction.
- The clinical phenotype is a flaccid, motor-predominant paralytic illness.



Schematic

# Flaccid paralysis is a functional consequence

- A contracting muscle requires successful neurotransmission.
- In botulism, chemical communication from motor axon to myofiber is interrupted.
- This differs from direct necrosis or primary inflammatory destruction of myofibers.

## Neurotransmission defect

ACh unavailable

Contractile trigger fails

## Primary muscle destruction

Myofiber injury

Different histologic substrate

# Botulism versus tetanus: Shared family, opposite pattern

- Both toxins inhibit neurotransmitter release, as Chapter 8.
- Botulinum toxin blocks acetylcholine release at the motor endplate.
- Tetanus toxin blocks inhibitory neurotransmission and produces spastic paralysis.

## Botulism

Peripheral motor terminal

Flaccid paralysis


## Tetanus

Inhibitory pathways affected

Spastic paralysis

# Anatomic target predicts paralysis phenotype

- Direct loss of excitatory drive to skeletal muscle produces flaccidity.
- Loss of inhibitory control over motor neurons instead creates excessive activation.
- The direction of synaptic effect is more informative than the bacterial genus alone.



Schematic

## Severe dysfunction can lack specific histology


- Neuropathologic changes in botulinum and tetanus toxicity may be subtle and nonspecific.
- Absence of a diagnostic structural lesion does not exclude a profound functional blockade.
- The diagnosis therefore depends heavily on clinical features and toxin-specific investigations.

**Function  $\neq$  morphology**

Severe paralysis may coexist with nonspecific tissue findings

# The recognizable descending motor pattern

- Botulism typically begins with cranial nerve dysfunction.
- Weakness may then extend to neck, trunk, and extremities.
- Progression can involve upper airway and respiratory muscles.



Schematic

# Ocular and facial weakness direct attention to the junction

- Diplopia, ptosis, or other cranial nerve palsies can precede generalized weakness.
- Cranial findings should prompt examination of speech, swallowing, and breathing.
- The phenotype alone is not pathognomonic: Immune junction disorders overlap.

## **Cranial involvement**

Ocular movement

Facial strength


## **Bulbar involvement**

Speech

Swallowing and  
airway safety

# Bulbar dysfunction can threaten the airway

- Dysarthria, dysphagia, nasal voice, and poor secretion handling imply bulbar impairment.
- Aspiration risk and upper-airway obstruction may develop before overt diaphragmatic failure.
- Serial clinical assessment is essential when weakness progresses.



Schematic

# Autonomic symptoms add diagnostic clues

- Botulinum toxin can impair cholinergic autonomic transmission.
- Dry mouth, constipation or ileus, and urinary retention are relevant examination findings.
- These features should be interpreted with cranial and motor abnormalities, not in isolation.

## Somatic motor effects

Cranial weakness

Limb/respiratory weakness

## Autonomic effects

Dry mouth / dry eyes

Urinary and bowel dysfunction

# Respiratory failure is the principal immediate threat

- Weakness of respiratory muscles compromises ventilation.
- Bulbar dysfunction may independently undermine airway protection.
- Respiratory muscle involvement as a potentially fatal consequence.

## **Ventilatory pump**


Diaphragm and chest muscle strength

## **Airway protection**

Bulbar and swallowing function

# A mechanism-to-symptom map


- Blocked acetylcholine release impairs muscle activation.
- Cranial and bulbar dysfunction produces ocular, speech, and swallowing abnormalities.
- More extensive blockade can produce limb and breathing-muscle weakness.



Schematic

# Clinical recognition precedes laboratory proof

- Consider botulism in progressive descending flaccid weakness with cranial neuropathies.
- Exposure history narrows the possibilities but may initially be unavailable.
- Laboratory confirmation is valuable; Urgent treatment decisions are clinical.



Schematic


# A focused bedside neurologic examination

- Document cranial nerve, facial, palate, tongue, speech, and swallowing function.
- Grade limb and neck strength repeatedly, not just on presentation.
- Reassess respiratory effort and autonomic dysfunction as the course evolves.

| Domain         | Priority finding                 |
|----------------|----------------------------------|
| Cranial/bulbar | Eye movements, voice, swallow    |
| Motor          | Neck and limb strength           |
| Respiratory    | Effort, ventilation, airway      |
| Autonomic      | Dryness, bowel, urinary function |

# Serial respiratory assessment is more informative

- Respiratory decline may occur during observation even after mild initial weakness.
- Track clinical work of breathing together with objective measures where feasible.
- Facial weakness can impair the mouth seal needed for conventional spirometry.



Schematic


## Toxin detection confirms a clinical hypothesis

- Specialized laboratories may test serum, stool, gastric contents, or implicated food for toxin.
- Culture-based testing may identify toxin-producing clostridia in selected specimens.
- Testing must be coordinated with expert public health laboratories.

| Evidence source | Diagnostic purpose           |
|-----------------|------------------------------|
| Serum / stool   | Toxin detection              |
| Wound material  | Organism identification      |
| Implicated food | Exposure-source confirmation |

# Specimen collection must not delay treatment

- Serum is ideally obtained before antitoxin administration.
- Confirmation may take days and may be negative in genuine cases.
- Clinical urgency outweighs waiting for a laboratory report.



Schematic

# Antitoxin addresses circulating toxin

- The therapeutic objective is to neutralize toxin not yet bound to its neural target.
- It prevents additional progression more effectively than it reverses established blockade.
- Specialist consultation and prompt administration are emphasized by CDC guidance.

## Before neuronal binding

Antitoxin can neutralize

Progression may be limited


## After intracellular action

Established blockade persists

Supportive care remains essential

# Supportive care bridges the impaired transmission

- Airway and ventilatory support can be life-saving while paralysis resolves.
- Dysphagia requires careful attention to aspiration and nutrition.
- Progressive bulbar or respiratory weakness warrants high-acuity monitoring.



Schematic

# Infant botulism is a distinct treatment pathway

- Infant intestinal colonization produces toxin within the gut.
- Clinical suspicion requires prompt consultation; Do not wait for laboratory confirmation.
- Specific human-derived botulism immune globulin is used for eligible infant cases in the United States.

## Infant botulism

Intestinal toxemia

Human immune globulin (BabyBIG)

## Other symptomatic botulism

Exposure routes differ

Equine-derived antitoxin in US guidance

# Teaching vignette: Food-associated paralysis

- An adult develops diplopia, slurred speech, and progressive symmetric weakness after a shared meal.
- A second person who ate the same food is similarly affected.
- Question: Which junctional step best explains the syndrome?


## Discussion point

**Presynaptic ACh exocytosis is inhibited**

Illustrative case — not a patient report

# Reason through the foodborne vignette


- A clustered exposure makes ingested toxin a plausible explanation.
- Cranial nerve involvement plus descending weakness supports botulism.
- Prioritize respiratory assessment, public-health consultation, and time-sensitive antitoxin evaluation.



Schematic

# Curare: The contrasting postsynaptic toxin

- Curare refers to plant-derived muscle-relaxing substances.
- Its principal toxic action at the junction is blockade of acetylcholine receptors.
- The result is ineffective neuromuscular transmission and flaccid paralysis.



Schematic

# Historical curare and the motor endplate

- Robbins recounts curare use as an arrow poison by Indigenous communities of the Amazon.
- The observation that exposure produced paralysis helped identify receptor-level physiology.
- Its history is distinct from the mechanism of a bacterial neurotoxin.

## Historical use

Plant-derived arrow  
poisons

Observed paralytic  
effect

## Mechanistic insight

Postsynaptic  
receptor blockade

Failure of muscle  
activation

# Receptor blockade without transmitter suppression

- A motor neuron may continue releasing acetylcholine into the cleft.
- Curare prevents normal activation of endplate acetylcholine receptors.
- Therefore, the key deficit is ligand response rather than presynaptic release.

## Presynaptic function

ACh may be released

Vesicle fusion not primary target


## Postsynaptic function

Receptor occupied/blocked

Normal endplate response fails

# Why curare causes flaccid paralysis

- The postsynaptic receptor must be activated for a normal muscle response.
- Occupancy by a blocking antagonist interrupts that signal.
- The muscle remains functionally disconnected from an otherwise activated motor nerve.



Schematic

# Curare and medical neuromuscular blockers

- Historical use of curare as a surgical muscle relaxant.
- Modern agents with a related receptor-blocking mechanism replaced it in routine practice.
- Controlled anesthesia use and unintended neuromuscular toxicity should not be equated.

## Historical curare

Plant-derived agent

Obsolete surgical  
use

## Modern clinical analogy

Pharmacologic  
receptor blockade

Managed in  
anesthetic care

## Compare curare with botulinum toxin directly

- Botulinum toxin: Failed acetylcholine liberation from the motor terminal.
- Curare: Failed acetylcholine recognition at the endplate receptor.
- Both can leave downstream muscle activation insufficient.

| Characteristic   | Botulinum toxin             | Curare                  |
|------------------|-----------------------------|-------------------------|
| Origin           | Bacterial neurotoxin        | Plant-derived compounds |
| Primary site     | Presynaptic                 | Postsynaptic            |
| Molecular effect | Inhibits vesicle exocytosis | Blocks ACh receptors    |
| Motor result     | Flaccid paralysis           | Flaccid paralysis       |

# Myasthenia gravis shares a postsynaptic location

- ACh receptor autoantibodies reduce receptor availability and function.
- Curare blocks receptor function through a nonimmune toxic mechanism.
- Myasthenic weakness commonly fluctuates with exertion and may affect ocular muscles.

## Myasthenia gravis

Autoimmune  
receptor  
dysfunction

Fluctuating,  
fatigable weakness

## Curare

Direct receptor  
blockade

Toxic/pharmacologi  
c exposure

## Lambert–Eaton shares a presynaptic location

- Lambert–Eaton syndrome impairs ACh release by targeting presynaptic calcium channels.
- Botulinum neurotoxin impairs later vesicle-fusion machinery.
- Strength often improves with brief repeated activity in Lambert–Eaton syndrome.

### Lambert–Eaton

Immune calcium-channel defect

Facilitation with activity

### Botulinum neurotoxin

SNARE cleavage

Exposure-related paralysis

## Same compartment does not mean same mechanism

- At the presynaptic terminal, ion-channel dysfunction differs from vesicle-fusion blockade.
- At the postsynaptic membrane, antibody-mediated receptor loss differs from receptor antagonism.
- Etiology, trajectory, and exposure history remain essential to diagnosis.

| Compartment  | Immune disorder                           | Toxic disorder               |
|--------------|-------------------------------------------|------------------------------|
| Presynaptic  | Lambert–Eaton (Ca <sup>2+</sup> channels) | Botulinum toxin (exocytosis) |
| Postsynaptic | Myasthenia gravis (AChR / MuSK)           | Curare (AChR blockade)       |

# Distinguish botulism from other acute weakness

- Guillain–Barré syndrome and myasthenia gravis may overlap clinically with botulism.
- A descending cranial-onset pattern and relevant exposure history support botulism.
- No single symptom replaces comprehensive neurologic examination or appropriate testing.

## Botulism clues

Cranial-onset  
descending  
weakness

Exposure / outbreak  
connection


## Competing diagnoses

Other junction  
disorders

Acute neuropathic  
weakness

# A mechanistic diagnostic map

- Begin with the phenotype: Painless flaccid weakness and the affected motor regions.
- Assess toxic exposure, immune features, familial onset, and progression.
- Use electrophysiology, serology, or toxin testing as appropriate to the working diagnosis.



Schematic

## Clinical pitfall: Normal morphology is not reassurance


- Botulinum-associated pathology may show only subtle nonspecific changes.
- Diagnosis is not ruled out by a structurally unremarkable muscle biopsy.
- Mechanistic interpretation and respiratory surveillance can matter more than routine histology.

**Transmission can fail**

Even without a specific histopathologic signature

## Clinical pitfall: Do not await definitive tests

- Suspected botulism is a clinical and public-health emergency.
- Laboratory studies support diagnosis and investigation but results may lag.
- Early expert consultation, antitoxin evaluation, and monitoring must proceed in parallel.



Schematic

# Teaching vignette: Postsynaptic blockade

- During a controlled anesthetic procedure, a muscle relaxant prevents movement despite motor stimulation.
- Presynaptic transmitter release is not the intended target.
- Question: Which functional compartment is blocked?


## Discussion point

**Postsynaptic nicotinic ACh  
receptor**

Illustrative pharmacology scenario

# Explain the postsynaptic vignette


- Receptor antagonism impairs the endplate response despite available acetylcholine.
- The physiologic analogy is curare rather than botulinum toxin.
- This distinction separates pharmacologic motor paralysis from presynaptic neurotoxic exocytosis failure.



Schematic

# Two toxins, two molecular targets, one motor outcome

- Botulinum neurotoxin cleaves secretory machinery and prevents ACh exocytosis.
- Curare prevents ACh receptor activation at the muscle membrane.
- Both culminate in deficient neuromuscular activation and flaccid weakness.



**No ACh released** Schematic **ACh cannot activate receptor**

## Five facts that should survive the lecture

- The neuromuscular junction transduces motor-neuron activity into muscle contraction.
- Botulism is a toxin-mediated presynaptic exocytosis disorder.
- Curare produces postsynaptic ACh receptor blockade.
- Flaccid paralysis can be severe without characteristic tissue destruction.
- Botulism requires rapid clinical recognition and respiratory-risk evaluation.

# Apply the localization rule

- If acetylcholine cannot enter the cleft, focus on the presynaptic release apparatus.
- If transmitter is released but its receptor cannot be activated, focus on the endplate.
- Presynaptic vs postsynaptic localization organizes toxin mechanisms and important differentials.

## No transmitter delivered

Botulinum toxin

Presynaptic fusion defect

## Transmitter not received

Curare

Postsynaptic receptor defect

## Primary and supplementary references

- Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. (2026). Ch. 27, pp. 1115–1116; Ch. 8, pp. 311, 346.
- Rao AK et al. Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021. MMWR Recomm Rep. 70(2):1–30.
- CDC. Clinical Overview of Infant Botulism. Updated September 29, 2026.
- Rossetto O et al. The metallo-proteinase activity of tetanus and botulism neurotoxins. J Physiol Paris. 1995;89:43–50.